Skip to main content
. 2024 Feb 21;14(2):e077408. doi: 10.1136/bmjopen-2023-077408

Figure 4.

Figure 4

Risk of hospitalisation associated with immunosuppressive drug class exposure (selective immunosuppressants, tumour necrosis factor inhibitors, interleukin inhibitors, calcineurin inhibitors, systemic corticosteroids, and other immunosuppressants including rituximab) in patients with immune-mediated inflammatory diseases (IMID).